...

An Advocate’s Guide to Attending Scientific Meetings

Two graduates of the AACR Scientist↔Survivor Program share tips for getting the most out of large scientific conferences.




...

​The Evolving Role of Patient Advocacy

AACR’s Scientist↔Survivor Program marks a milestone as patient advocates continue to shape research and policy.




...

Pembrolizumab Shows Further Promise for Melanoma

In a phase III clinical trial, pembrolizumab yielded a 75.4 percent recurrence-free survival rate after 12 months among patients whose stage III melanoma tumors had been fully resected. ​



...

Cancer Researchers Offer Reasons for Optimism

Cancer researchers and patient advocates spoke about progress against cancer at a public education forum sponsored by the American Association for Cancer Research.



...

Non–Small Cell Lung Cancer Takes Center Stage

A trio of clinical trials at the AACR Annual Meeting spotlight new avenues for non–small cell lung cancer treatment.




...

A New Type of Drug Approval

At the AACR Annual Meeting, researchers and regulators discuss what it means to tie approval of an immunotherapy to tumors’ molecular characteristics, not to their tissues of origin.



...

Artificial Intelligence Characterizes Cancer

At the AACR Annual Meeting 2018, researchers at Google compared the speed and accuracy of human pathologists and computer algorithms in diagnosing and grading cancer.



...

​Supporting Survivors

Panel of experts discuss survivorship challenges and potential areas for study.




...

A Response to Roadblocks

The Biden Cancer Initiative Colloquium gathered experts to discuss obstacles preventing access to care at the AACR Annual Meeting.




...

Focusing on the Fundamentals

National Cancer Institute director Norman “Ned” Sharpless meets with advocates and outlines areas of focus for the agency.




...

The Many Faces of Patient Advocacy

Advocates shared their stories and projects at the AACR Annual Meeting.




...

The Ins and Outs of Tumor Testing

In a session at the AACR Annual Meeting, oncologists discussed the state of cancer precision medicine—and engaged with patient advocates.​